Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 9 Issue 3, September 2015

Volume 9 Issue 3

In this issue...

• Neuroscience set for deal spree

• Evolving approaches in age-related disorders

• Partnering to manipulate the microbiome

Cover image: Brain Intelligence Discovery. wildpixel / Getty Images

Neuroscience set for deal spree

    Feature

  • Profiles

  • Advertisement Feature |

    New company Astrocyte Pharmaceuticals is pioneering a novel approach to healing a damaged brain that involves activating energy supplies in astrocytes, the abundant star-shaped brain cells with a central role in repairing CNS injury.

  • Advertisement Feature |

    Sanford Burnham Prebys Medical Discovery Institute is an independent, nonprofit biomedical research institute that combines deep expertise in fundamental and translational science to discover innovative medicines and diagnostics.

  • Advertisement Feature |

    The Institut Pasteur is harnessing a powerful combination of in-house research strengths to explore the relationship between the microbiome and the brain. The institute is looking for partners eager to take advantage of this unique opportunity to learn more about the gut–brain axis.

  • Advertisement Feature |

    Probiodrug’s novel approach targets a modified form of β-amyloid, which has a key role in the creation of toxic Aβ oligomers. The company’s lead product is a first-in-class oral small-molecule glutaminyl cyclase inhibitor.

Evolving approaches in age-related disorders

    Feature

  • News Feature |

    Although specific age-related disorders such as Alzheimer’s disease continue to be a focus of research and development investment and dealmaking activity, companies are also beginning to approach aging in a broader way.

    • Suzanne Elvidge
  • Profile

  • Advertisement Feature |

    Regenerative medicine company International Stem Cell Corporation (ISCO) leads the way in developing new treatments for Parkinson’s disease and other clinical conditions using a unique stem cell approach.

Partnering to manipulate the microbiome

    Feature

  • Profiles

  • Advertisement Feature |

    Using a unique combination of computational chemistry, pharmacology and cheminformatics methods, Re-Pharm is successfully reprofiling marketed compounds as early stage candidates ready for partnering.

Search

Quick links